和黄医药

We will host a physician expert call with a professor and key opinion leader in immune thrombocytopenia (ITP), to discuss the treatment landscape of ITP via webcast on Wednesday, August 28, 2024, at 7:00 p.m. HKT. The event will be held in Chinese (Putonghua) and can be accessed via https://lnkd.in/gfhuPYFS The transcript of the event, including an English translation, will be available shortly thereafter for approximately 90 days. This event is intended for investor audiences only. ESLIM-01 is a Phase III trial of HUTCHMED’s novel investigational drug candidate sovleplenib in patients with primary ITP in China. The trial met all its endpoints and results were published in The Lancet Haematology and orally presented at the European Hematology Association (EHA) Hybrid Congress. HUTCHMED filed a New Drug Application in China in January 2024 for sovleplenib.

We are happy to share that we’ve established our new R&D center at the Hong Kong Science Park. Founded in 2000, HUTCHMED has emerged from a trailblazer in novel drug discovery, to a major player in China’s biotech industry.   We plan to focus on translational research and AI-driven drug discovery and the development of therapeutics for novel targets and diseases with high unmet medical needs at our Hong Kong R&D center. Leveraging HKSTP - Hong Kong Science and Technology Parks Corporation’s thriving biotech ecosystem comprising over 270 companies, HUTCHMED is set to drive groundbreaking pharmaceutical interventions.   A welcoming ceremony was hosted by HKSTP. Professor Sun Dong, Secretary for Innovation, Technology and Industry of the Hong Kong SAR government; Albert Wong, CEO of HKSTP; Gracie Ng, Chief of Staff of HKSTP; Dr Grace Lau, Head of Institute for Translational Research (ITR) of HKSTP; Dr Dan Eldar, Chairman of HUTCHMED; Dr Weiguo Su, CEO and CSO of HUTCHMED; Dr Michael Shi, Head of R&D and Chief Medical Officer of HUTCHMED and notable representatives and guests from both HKSTP and HUTCHMED attended the ceremony.   Professor Sun Dong, Secretary for Innovation, Technology and Industry said,” The Hong Kong Government’s commitment to enhancing Hong Kong’s R&D capabilities, particularly in the field of biotechnology, is unwavering. With our robust research capability, top-notch universities, advanced research facilities and increasingly vibrant ecosystem, Hong Kong is well-placed as one of the most desirable destinations to provide an integrated platform for biotech companies to innovate and translate their excellent R&D outcomes into clinical trials and commercialization. The agglomeration of more biotech companies like HUTCHMED in Hong Kong will create synergies to further strengthen our city’s advantage in life and health technology industry.”   Dr Weiguo Su, Chief Executive Officer and Chief Scientific Officer of HUTCHMED, said, “HUTCHMED has built a deep pipeline with multiple products approved in China and around the globe, with two of them also approved in Hong Kong. The establishment of the Research Centre in Hong Kong marks a new chapter for HUTCHMED. We believe it is an important step to accelerate and expand our global research and development activities. We are grateful for the support from the HKSAR government and the HKSTP, and look forward to working together in the future to bring more innovative therapies to patients worldwide.”   Albert Wong, CEO of HKSTP said,” It is a thrilling moment as we welcome HUTCHMED’s landing at Science Park. HKSTP’s extensive network connects our companies with a global array of thousands of investors and partners, accelerating the development and deployment of innovative therapies. With HUTCHMED's expertise and commercialization capabilities, the collaboration will provide invaluable insights to our local biotech firms and benefit the broader community.”

We're #hiring a new Associate Director, Medical Writing in Florham Park, New Jersey. Apply today or share this post with your network.

We are delighted to report our 2024 Interim Results and provide updates on key clinical and commercial developments. https://lnkd.in/g3QUN4Vf HUTCHMED has delivered strong performance in the first half of this year. Our team has made significant progress implementing our strategy in discovering and developing novel, effective medicines; conducting clinical trials in our home market and in the global markets; and rapidly advancing regulatory and commercial goals.

We will be announcing our 2024 interim results on Wednesday, July 31, 2024 at 7am Eastern Daylight Time (EDT) / 12 noon British Summer Time (BST) / 7pm Hong Kong Time (HKT). Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by HUTCHMED management. https://lnkd.in/gQNr5nvR

Since HUTCHMED began its sustainability journey in 2020, we have been integrating sustainability into every aspect of our business decisions and operations, strengthening our governance and endeavoring to align with the latest disclosure requirements, thereby striving to achieve industry best practice.   HUTCHMED scored 49 in the 2023 S&P Global ESG Ratings (90th percentile), significantly higher than the pharmaceutical industry average of 31 points. Mark Lee, Senior Vice President (Corporate Management and Communications) of HUTCHMED, was invited by S&P Global Market Intelligence to share insights on the topic "Unlocking the Potential of Sustainability Data" to more than 300 professionals from various industries around the world at its annual forum held in Hong Kong. Together with other panelists Francis Tong and Olivier Trecco, Mark shared how HUTCHMED has progressed and benefited from taking a more efficient and strategic-focused approach to ESG by upholding the importance of data granularity, including the full spectrum of Scope 3 data, within the Company. Please visit our website to learn more about HUTCHMED’s sustainability: https://lnkd.in/gY4X9aHU

We are happy to share the successful conclusion of our 2024 R&D Day held in Shanghai and through webcast. Over 50 investors attended the event in person and approximately 450 joined online. Our management team shared the latest research advancements and pipeline progress, focusing on three drug candidates poised to address significant global unmet needs: Sovleplenib, our first potential novel medicine for autoimmune diseases; Surufatinib, a potential novel treatment for metastatic pancreatic ductal adenocarcinoma (PDAC); and our IDH1/2 dual inhibitor for acute myeloid leukemia (AML). Listen to the replay: https://lnkd.in/g6MbtnYs

On July 4, 2024, Hong Kong Investor Relations Association (HKIRA) announced the winners of its 10th Investor Relations Awards 2024. HUTCHMED received four awards in the categories of “Best IR by Chairman/CEO”, “Best IR Company”, “Best IR Team” and “Best ESG (E)”. https://lnkd.in/gz67Xp6E Despite the volatile and challenging global economy and market condition, HUTCHMED team remains steadfast in executing our global vision of bringing innovative medicines to patients the world over. Over the last 12 months, we held over 700 meetings with investors through roadshows and conferences throughout China and around the world. There are now 34 sell-side analysts covering HUTCHMED’s stock. Our team will continue to work hard to increase transparency of disclosure, maintain equitable distribution of information, as well as provide prompt and accurate response to queries from investors and other stakeholders.

We are happy to share that the New Drug Application for tazemetostat for the treatment of adult patients with relapsed or refractory follicular lymphoma has been accepted for review and granted Priority Review by the China National Medical Products Administration (NMPA). https://lnkd.in/gFYzVcvJ

We will host in-person presentation and online webinar on Tuesday, July 9, 2024 to share insights into our R&D strategy and vision. Our senior management team will provide updates on certain programs within HUTCHMED’s extensive and innovative pipeline. This will include updates on the Phase III ESLIM‑01 and Phase II/III ESLIM‑02 studies of our Syk inhibitor sovleplenib in ITP and wAIHA respectively; the surufatinib Phase II/III study for metastatic pancreatic ductal adenocarcinoma; and the Phase III RAPHAEL study of our IDH1/2 inhibitor HMPL-306 in acute myeloid leukemia. https://lnkd.in/dVdSwS-F